institutionsInstitution
Breast International Group (BIG)
The Breast International Group is the umbrella for 50+ academic breast cancer groups worldwide and co-sponsor of OlympiA, APHINITY, and HERA.
Founded 1999 by Martine Piccart. Coordinates academic breast trials across >60 groups and >10,000 hospitals: HERA (adjuvant trastuzumab), APHINITY (pertuzumab), MINDACT (MammaPrint), OlympiA (adjuvant olaparib with NRG Oncology).
Location
Brussels, BE
Type
consortium
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#112 · 32 points (0 Newsweek + 0 NCI + 32 from 16 linked objects) · ranking
- OlympiA (with NRG)
- HERA / APHINITY
- MINDACT
David Cameron
Professor of Oncology, University of Edinburgh; Chair, Breast International Group
Breast cancerAdjuvant trialsTrial governance
David Cameron is a breast oncologist who chairs the Breast International Group.
Evandro de Azambuja
Head of Medical Support Team, Institut Jules Bordet; Medical Oncologist
Breast cancerCardio-oncologyAdjuvant HER2 therapy
Evandro de Azambuja is a breast oncologist who studies heart safety of HER2-targeted therapy in BIG trials.
Martine Piccart
Scientific Director, Institut Jules Bordet; Co-founder, Breast International Group
Breast cancerAdjuvant trastuzumabInternational trial networks
Co-founded the Breast International Group and led HERA, the trial that made adjuvant trastuzumab standard.
cancers
3drugs
2institutions
9Austrian Breast & Colorectal Cancer Study GroupBreast Cancer TrialsComprehensive Cancer Center Vienna – Medical University of Vienna / AKHEdinburgh Cancer Centre / CRUK Scotland CentreETOP IBCSG Partners FoundationGEICAM Spanish Breast Cancer GroupInstitut Jules BordetNRG OncologySOLTI Cancer Research Group